Comparative activity of ertapenem and piperacillin-tazobactam in a murine systemic infection model with Bacteroides fragilis and Escherichia coli
It is now well-recognized that most intra-abdominal infections involve multiple types of bacteria. The most frequently encountered organisms in intra-abdominal infections are Escherichia coli and Bacteroides fragilis. These two micro-organisms are indigenous components of faecal microbiota, but can cause intra-abdominal abscess following surgery (Goldstein & Snydman, 2004) . Therefore, an effective antimicrobial agent for the treatment of intra-abdominal infections requires a broad spectrum of activity against both aerobic and anaerobic bacteria.
Ertapenem is a new carbapenem with a broad spectrum of activity against Gram-negative pathogens, including extended-spectrum-b-lactamase and AmpC-producing Enterobacteriaceae, as well as against Gram-positive aerobic and anaerobic pathogens (Goldstein & Snydman, 2004; Wexler, 2004) . Clinical trials involving complicated intraabdominal infections demonstrated that ertapenem has equivalent efficacy and safety when compared with piperacillin-tazobactam (Solomkin et al., 2003; Dela Pena et al., 2006) . However, in the setting of mixed infections, antimicrobial therapy may result in clinical improvement and a decrease in bacterial burden without, necessarily, eradicating the infection. There are no in vivo time-kill studies regarding ertapenem and piperacillin-tazobactam pharmacodynamics. Thereby, in the present study, we compared the in vivo activity of ertapenem with that of the piperacillin-tazobactam combination in a murine systemic mixed infection model.
A piperacillin-tazobactam preparation (Tazocin; Lederle Piperacillin) and ertapenem sodium (Invanz; Merck Sharp & Dohme) were purchased commercially and solubilized in sterile saline (0.9 % NaCl) for injection. For MIC determinations, ertapenem sodium was kindly provided as standard powder by Merck Sharp & Dohme. B. fragilis (ATCC 25285) and E. coli (ATCC 25922) were used throughout the experiments. The obligate anaerobe B. fragilis was incubated anaerobically at 37 u C in an anaerobic chamber (Forma Scientific) containing an atmosphere of 85 % N 2 , 10 % H 2 and 5 % CO 2 , and the facultative anaerobe E. coli was incubated aerobically or anaerobically at 37 u C.
MICs of the test drugs were determined before and after antimicrobial therapy by the agar dilution method, according to the recommendations of the Clinical Laboratory Standards Institute (formerly the National Committee for Clinical Laboratory Standards) (NCCLS, 2003 (NCCLS, , 2004 .
All experimental procedures with animals were approved by the ethics committee in animal experimentation of the Universidade Federal de Minas Gerais (CETEA/UFMG). Female Swiss mice (Animal Care Center, Universidade Federal de Minas Gerais, Brazil), 3 weeks old and weighing 15 to 18 g, were inoculated intraperitoneally with 0.1 ml of a mixed culture containing about 10 7 c.f.u. of each bacteria per mouse. The bacterial inoculum was prepared by suspending overnight cultures of B. fragilis and E. coli in 3 % porcine gastric mucin (Sigma-Aldrich), which were then mixed together in a volume ratio of 1 : 1.
In pharmacokinetic studies, infected mice were treated 3 h after bacterial challenge with a single subcutaneous (sc) injection of either ertapenem (25 mg kg 21 ) or piperacillin-tazobactam (340 mg kg 21 ).
The concentration of antibiotics used was extrapolated from the human equivalent dose as described by Freireich et al. (1966) . Blood samples were collected using cardiac puncture at 0.25, 0.5, 1, 2, 3 and 6 h post-injection (n54 per group). Blood samples were processed to plasma by centrifugation (3000 g, 10 min, 4 u C) and stored at 280 u C until needed for analysis. Antibiotic concentrations were determined in quadruplicate by an agar diffusion bioassay (Chapin-Robertson & Edberg, 1991) . E. coli ATCC 25922 was used as the indicator organism for both drugs. Standard curves were determined using mouse plasma. Zones of inhibition were measured to the nearest 0.01 mm by a digital caliper (digimatic caliper; Mitutoyo). The linearity of the standard curves was assessed with a regression coefficient of ¢0.995, and intra-plate and inter-plate variations were ¡11 %. The limits of detection of the assay were 0.12 mg ertapenem ml 21 and 4 mg piperacillin-tazobactam ml 21 .
For bacterial titre studies, infected animals were administered four doses of ertapenem (25 mg kg 21 , sc) or piperacillin-tazobactam (340 mg kg 21 , sc) at 6 h intervals, starting 3 h after infection. A separate group of control animals received saline (0.9 % NaCl) following the same schedule as for mice treated with antibiotics. Just prior to antibiotic initiation, and at 3, 6, 9 and 21 h after the first injection, groups (n54) of control and drug-treated animals were sacrificed by cervical dislocation. Subsequently, samples of blood and peritoneal fluid from each animal were harvested. In all specimens collected, bacterial counts were determined by performing a 1 : 10 serial dilution in sterile PBS and then 0.1 ml aliquots of each dilution were plated onto selective medium: MacConkey agar (Difco) for E. coli and Bacteroides bile aesculin agar for B. fragilis. Viable colonies of E. coli were counted after overnight incubation at 37 u C, and B. fragilis colonies were counted after incubation for 48 h at 37 u C in an anaerobic chamber. Dilutions were performed to eliminate potential carryover effects. The limit of quantification was 300 c.f.u. ml 21 .
For each drug studied, analysis of variance (two-way ANOVA) was used to compare the effects between the different groups, followed by use of the Holm-Sidak method to compare treated and untreated groups two by two. P values of ,0.05 were considered significant. Table 1 ).
The pre-treatment E. coli counts were 6.7 and 6.1 log 10 c.f.u. ml 21 in the peritoneal fluid and blood, respectively. Analysis of the kill curves for peritoneal fluid and blood revealed that ertapenem exhibited significantly higher killing activity than piperacillin-tazobactam (P,0.05, two-way ANOVA) (Fig. 1a, b) . Until 6 h after the first dose, the E. coli counts in the peritoneal fluid and blood were similar for both treatments (P.0.05). However, at 9 h after the first dose, the E. coli counts in the peritoneal fluid and blood were reduced to a higher extent by ertapenem (23.8 and 24.2 log 10 c.f.u. ml 21 , respectively) compared with piperacillin-tazobactam (21.5 and 21.8 log 10 c.f.u. ml 21 , respectively). Ertapenem produced sustained suppression of counts, and eventually resolved the infection in the peritoneal fluid and blood by 21 and 9 h, respectively.
The pre-treatment B. fragilis counts were 4.6 and 4.1 log 10 c.f.u. ml 21 in the peritoneal fluid and blood, respectively. Analysis of the kill curves revealed that both drugs resolved the infection in the blood and peritoneal fluid by 3 and 6 h, respectively, although ertapenem exhibited significantly higher killing activity than piperacillin-tazobactam in the peritoneal fluid (P,0.05, two-way ANOVA) (Fig. 1c,  d ). Nine hours after the first dose, the B. fragilis counts in the peritoneal fluid and blood were reduced by ertapenem to 23.7 and 22.6 log 10 c.f.u. ml 21 , respectively. At the same time, piperacillin-tazobactam reduced the B. fragilis counts in the peritoneal fluid and blood to 22.3 and 21.8 log 10 c.f.u. ml 21 , respectively.
In the therapeutic concentration range, ertapenem is highly bound to plasma protein (95 %) and this phenomenon probably contributes to its long plasma half-life (Majumdar et al., 2002) . The main pharmacokinetic-pharmacodynamic parameter of carbapenems and penicillins, which are antibiotics with time-dependent killing activities, is the % t.MIC (Nix et al., 2004) . In the present model of systemic infection, the superior activity of ertapenem, mainly against E. coli, can be attributed, at least in part, to its longer plasma half-life in mice (resulting in a longer % t.MIC) when compared to piperacillin-tazobactam (Tables 1  and 2 ).
Both drugs exhibited similar activity against B. fragilis, probably due to a lower inoculum (~4.7 log 10 c.f.u. ml 21 )
detected just prior to the first dose. The influence of inoculum size of E. coli and B. fragilis on piperacillin-tazobactam activity has been described in other studies (Goldstein et al., 1991; König et al., 1998; Stearne et al., 2004) . König et al. (1998) demonstrated that piperacillin activity was diminished at least 128-fold when high inocula of E. coli ATCC 25922 were used. In a recent in vitro study we also demonstrated a bacteriostatic activity of (Santos et al., 2007) . Thus, this inoculum effect can be an alternative explanation for the higher activity of ertapenem against E. coli (starting inoculum of~6.4 log 10 c.f.u. ml
21
) compared with piperacillin-tazobactam. A caveat of the present study is that single strains of B. fragilis and E. coli were examined, and it remains to be determined whether the findings of this investigation extend to other strains.
In conclusion, the data from the present study demonstrated that although both drugs have been effective in the treatment of this model of mixed infection, ertapenem exhibited a higher activity against E. coli relative to piperacillintazobactam, in agreement with a previous time-kill study in vitro (Santos et al., 2007 
